
Mahajan, Vinay

From: Riemenschneider, Marion on behalf of Office, Vas Narasimhan (Gen)

Sent: Thursday, December 01, 2016 7:03 PM **Subject:** Important organizational announcement



Dear Colleagues,

We wanted to share with you all that Alessandro Riva has made the decision to leave Novartis to pursue a new, exciting opportunity.

Alessandro has built one of the strongest cancer medicine portfolios in the industry and established the OBU as the leader in targeted, oral therapies. His impact on the advancement of cancer treatment and the success of our company has been profound, and he leaves behind a legacy of development and regulatory excellence, a high bar for operational precision and an unparalleled passion for patients. Above all, Alessandro has developed medicines that have made a positive difference for millions of patients around the world. He will be greatly missed by us all.

While we are sad to see Alessandro go, we are very pleased that Jamie Freedman, M.D., Ph.D., will join the Global Drug Development organization as Head of Oncology Development on January 2, 2017. Jamie joins us from Medlmmune, a member of the AstraZeneca Group, where he served as Head of Clinical Development. He brings strong experience and expertise in drug development. Prior to Medlummune, Jamie was Head of Oncology Early R&D at GSK.

Jamie will join both the Global Development and Oncology leadership teams and report operationally to Vas as part of the GDD structure and functionally to Bruno in the Oncology Division.

Please join us in welcoming Jamie to the GDD and Oncology teams and in wishing Alessandro well in his new role.

Regards,

Vas & Bruno

For internal distribution only.

